lasmiditan succinate · Eli Lilly And Co · NDA 211280
Reyvow
Earliest generic entry, as listed · earliest of 3 marketed strengths
5 Dec 2037
Other strengths are listed to 6 Jul 2040; no marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11053214.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12071423 | product | 6 Jul 2040 |
| US 11053214 | substance, product, use U-1719 | 5 Dec 2037 |
| US 12257246 | use U-2718 | 7 Jul 2030 |
| US 7423050 | substance, product, use U-1719 | 17 Feb 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 211280 · 001 · RLD · discontinued | tablet, oral | EQ 50MG BASE | 6 Jul 2040 |
| 211280 · 002 · RLD · discontinued | tablet, oral | EQ 100MG BASE | 6 Jul 2040 |
| 211280 · 003 · RLD · discontinued | tablet, oral | EQ 200MG BASE | 5 Dec 2037 |